Phase 2 N=130 Enemas Before Elective Cesarean Section
Complications After Cesarean Section
Primary: Number of Participants With Bowel Sounds — 23; 31 participants — p=0.15
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 2 N=57 Dutch Acute HCV in HIV Study (DAHHS)
Hepatitis C · Human Immunodeficiency Virus
Primary: Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population. — 41 participants
Phase 2 N=17 A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 23.3; 24.4 Week — p=0.3644
Phase 2 N=85 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…
Phase 2 N=16 An Implantable Microneuromodulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects
Shoulder Pain Chronic
Primary: Relief of Chronic Shoulder Pain — 0; 0 participants
Phase 2 N=60 Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
Bladder Cancer
Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants
Phase 2 N=10 Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia
Alveolar Bone Loss · Loss of Teeth Due to Extraction · Edentulous Alveolar Ridge
Primary: Change in Bone Gain or Loss in Millimeters (Buccopalatal) — 7.7 mm
Phase 2 N=52 Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI — 5.87; 8.14; 6.26; 7.08 percent change per participant year
Phase 2 N=40 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316
Asthma
Primary: Number of Subjects With Adverse Events — 0; 0; 0; 0 participants
Phase 2 N=170 Study of Milk Allergy and Tolerance in Children
Food Hypersensitivity · Milk Hypersensitivity
Primary: Number of Participants With a Positive Progression in Tolerance of Baked Milk and Ultimately Unheated Milk in Dose Escalation Sub-arm Compared to Maintenance Sub-arm…
Phase 2 N=232 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) — 0; 0; 0; 0 subjects
Phase 2 N=105 A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
Prostate Cancer
Primary: Assess the Ability of 99mTc-MIP-1404 to Detect Prostate Cancer Within the Prostate Gland. — 94.2 % sensitivity
Phase 2 N=76 Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Antitumor Activity Based on Time to Tumor Progression (TTP). — 9.3 months
Phase 2 N=10 Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…